NOMAC Vaginal Ring
- User: Female
- Hormonal: Hormonal
-
Delivery type:
- Vaginal Ring
-
Intended Duration:
- Short-Acting
- Development Stage: Phase II
- Developer(s)/researcher(s): Dinox, Merck
Details
- API: Nomegestrol Acetate
- Target: Progesterone Receptor
-
Mechanism of Action:
- Ovulation Inhibition
- Inactive Materials: Silicone
- Regimen: Undetermined
- MPT: Not Potential MPT
- Promising Attributes: Developers indicated that a NOMAC-based ring might offer superior cycle control to commercially available IVRs
Product Status
2018 Ph II Trial Failed to Prove Non-Inferiority to Commercial Product
History
Dinox and Merck conducted a dose-finding study in 2018 for vaginal rings containing E2/ENG, E2/NOMAC, or ENG/EE (the approved NuvaRing product). Non-inferiority to NuvaRing could not be established for the investigational rings, including the NOMAC-based ring.